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Sandra L Edwards, Carol Gardiner, Alex Henderson, Simon T Holden, Tessa Homfray, Tracy Lester, Rebecca A Lewis, Ruth Newbury-Ecob, 
Katrina Prescott, Oliver W Quarrell, Simon C Ramsden, Eileen Roberts, Dagmar Tapon, Madeleine J Tooley, Pradeep C Vasudevan, Astrid P Weber, 
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Summary
Background Fetal structural anomalies, which are detected by ultrasonography, have a range of genetic causes, 
including chromosomal aneuploidy, copy number variations (CNVs; which are detectable by chromosomal 
microarrays), and pathogenic sequence variants in developmental genes. Testing for aneuploidy and CNVs is routine 
during the investigation of fetal structural anomalies, but there is little information on the clinical usefulness of 
genome-wide next-generation sequencing in the prenatal setting. We therefore aimed to evaluate the proportion of 
fetuses with structural abnormalities that had identifiable variants in genes associated with developmental disorders 
when assessed with whole-exome sequencing (WES).
Methods In this prospective cohort study, two groups in Birmingham and London recruited patients from 34 fetal 
medicine units in England and Scotland. We used whole-exome sequencing (WES) to evaluate the presence of genetic 
variants in developmental disorder genes (diagnostic genetic variants) in a cohort of fetuses with structural anomalies 
and samples from their parents, after exclusion of aneuploidy and large CNVs. Women were eligible for inclusion if 
they were undergoing invasive testing for identified nuchal translucency or structural anomalies in their fetus, as 
detected by ultrasound after 11 weeks of gestation. The partners of these women also had to consent to participate. 
Sequencing results were interpreted with a targeted virtual gene panel for developmental disorders that comprised 
1628 genes. Genetic results related to fetal structural anomaly phenotypes were then validated and reported postnatally. 
The primary endpoint, which was assessed in all fetuses, was the detection of diagnostic genetic variants considered 
to have caused the fetal developmental anomaly.
Findings The cohort was recruited between Oct 22, 2014, and June 29, 2017, and clinical data were collected until 
March 31, 2018. After exclusion of fetuses with aneuploidy and CNVs, 610 fetuses with structural anomalies and 
1202 matched parental samples (analysed as 596 fetus-parental trios, including two sets of twins, and 14 fetus-parent 
dyads) were analysed by WES. After bioinformatic filtering and prioritisation according to allele frequency and effect 
on protein and inheritance pattern, 321 genetic variants (representing 255 potential diagnoses) were selected as 
potentially pathogenic genetic variants (diagnostic genetic variants), and these variants were reviewed by a 
multidisciplinary clinical review panel. A diagnostic genetic variant was identified in 52 (8∙5%; 95% CI 6·4–11·0) of 
610 fetuses assessed and an additional 24 (3∙9%) fetuses had a variant of uncertain significance that had potential 
clinical usefulness. Detection of diagnostic genetic variants enabled us to distinguish between syndromic and non-
syndromic fetal anomalies (eg, congenital heart disease only vs a syndrome with congenital heart disease and 
learning disability). Diagnostic genetic variants were present in 22 (15∙4%) of 143 fetuses with multisystem 
anomalies (ie, more than one fetal structural anomaly), nine (11∙1%) of 81 fetuses with cardiac anomalies, and 
ten (15∙4%) of 65 fetuses with skeletal anomalies; these phenotypes were most commonly associated with diagnostic 
variants. However, diagnostic genetic variants were least common in fetuses with isolated increased nuchal 
translucency (≥4∙0 mm) in the first trimester (in three [3∙2%] of 93 fetuses).
Interpretation WES facilitates genetic diagnosis of fetal structural anomalies, which enables more accurate predictions 
of fetal prognosis and risk of recurrence in future pregnancies. However, the overall detection of diagnostic genetic 
variants in a prospectively ascertained cohort with a broad range of fetal structural anomalies is lower than that 
suggested by previous smaller-scale studies of fewer phenotypes. WES improved the identification of genetic disorders 
in fetuses with structural abnormalities; however, before clinical implementation, careful consideration should be 
given to case selection to maximise clinical usefulness.
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Introduction
Approximately 3% of pregnancies will show a fetal 
structural anomaly in a sonogram, which can range from a 
single minor defect to severe multisystem anomalies that 
are fatal.1 Genetic investigations are important in the 
evaluation and clinical triage of fetal structural anomalies. 
For more than 30 years, conventional prenatal cytogenetic 
analysis was the first-line method to investigate these 
anomalies but, within the last 10 years, chromosomal 
microarray analysis has been increasingly adopted to 
detect submicroscopic pathogenic copy number varia-
tions (CNVs) in prenatal diagnoses.2,3 The addition of 
chromosomal microarray testing to karyotyping increases 
the frequency of detection of chromosomal abnormalities 
by 3–5%.2–4 Fetal structural anomalies can be associated 
with all types of genetic variation including aneuploidy, 
uniparental disomy, CNVs, and intragenic mutations. 
There is increasing interest in genome-wide sequencing 
strategies to investigate prenatally detected congenital 
abnormalities. Prenatal whole-genome sequencing 
(WGS) has previously been described,5 but whole-exome 
sequencing (WES) and targeted gene panels have received 
more interest because of their lower cost, the lower 
amounts of fetal DNA required, the possibility of com-
paratively more rapid turnaround, and greater sequencing 
depth.6–13 We previously used WES in 29 fetal-parental trios 
with a fetal structural anomaly, and we identified an 
underlying genetic cause in 10% of cases.7 In the 
investigation of a range of fetal structural anomalies, 
WES has shown variants in genes associated with 
developmental disorders in more than 50% of fetuses in 
investigated cohorts, but most previous studies14,15 have 
used small sample sizes (of 30 fetuses or fewer), are 
confined to highly selected subgroups (eg, those that were 
attained at autopsy), or both (appendix).
To determine the usefulness of genome-wide se-
quencing strategies in prenatal diagnosis of fetal structural 
anomalies a large-scale sequencing project, the Prenatal 
Assessment of Genomes and Exomes (PAGE) study, was 
established. In our study, as part of this larger project, we 
aimed to report the WES results from 610 fetuses 
(and parental samples) with a wide range of fetal structural 
anomalies, and to highlight the ethical and practical issues 
that we encountered that have implications for the 
translation of prenatal WES into clinical practice.
Methods
Study design and participants
In this prospective cohort study, two groups in 
Birmingham and London recruited patients from 34 fetal 
medicine units in England and Scotland (appendix). 
If fetal structural anomalies were detected during a 
Research in context
Evidence before this study
Approximately 3% of pregnancies will show a fetal structural 
anomaly in a routine prenatal ultrasound, and genetic 
investigations are important in assessment of these cases. 
Chromosomal microarray analysis, which increases the frequency 
of diagnoses of chromosomal abnormalities by 3–5%, 
has increasingly superseded conventional cytogenetic testing. 
There is increasing interest in genome-wide sequencing 
strategies, such as whole-exome sequencing (WES), in 
identification of genetic causes of congenital abnormalities and 
the addition of WES to chromosomal microarray has greatly 
increased the frequency with which genetic causes are detected 
through genetic testing in children with developmental 
disorders. However, evidence regarding the usefulness of WES for 
fetal structural anomalies is inadequate. We searched PubMed 
for studies of whole-exome or genome sequencing that had 
been published in English on or before Nov 1, 2017. We used the 
search terms “genome”, “anomaly”, and “malformation” to 
identify relevant studies. Most reports included a small 
number (<30 cases) of highly selected subgroups of fetuses with 
a narrow range of structural anomalies and provided inadequate 
information regarding the likely frequency with which genetic 
causes are detected from the application of WES for a broad 
range of fetal structural anomalies in clinical practice.
Added value of this study
To our knowledge, this is the first large-scale prospectively 
ascertained cohort of fetal structural anomalies that has been 
detected with prenatal ultrasound (in which aneuploidy and 
large copy number variants had been excluded). After 
bioinformatic filtering of the WES data according to allele 
frequency and effect on protein and inheritance pattern and 
assessment by a multidisciplinary clinical review panel as to 
whether a WES finding was pathogenic and causative, we 
detected diagnostic abnormalities in 8·5% of fetuses with 
structural anomalies. These data suggest that the addition of 
prenatal WES to chromosomal microarray would increase the 
detection of genetic causes of fetal structural anomalies and 
would provide important information on prognosis and future 
recurrence risks.
Implications of all the available evidence
Although WES increases the frequency of identification of 
genetic causes of structural anomalies in fetuses more than 
cytogenetics or chromosomal microarray alone, the overall 
frequency of diagnostic genetic findings in a series 
comprising a broad range of prenatally detected fetal 
structural anomalies is lower than was previously reported in 
smaller, more biased series of fetus structural anomalies and 
in children with developmental disorders who had been 
selected after genetic evaluation. Given the practical, 
diagnostic, and ethical challenges of prenatal diagnosis, 
genome-wide sequencing for fetal structural anomalies is 
best applied to selected subgroups (eg, those with multiple 
congenital anomalies) or after genetic review.
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routine detailed ultrasound scan at any of these units, 
parents who opted for invasive testing were offered 
participation in the PAGE study.
Women were eligible for inclusion if they were under-
going invasive testing for identified nuchal translucency 
or structural anomalies in their fetus, as detected by 
ultrasound after 11 weeks of gestation. The partners of 
these women also had to consent to participate. Women 
were excluded if abnormal aneuploidy considered to 
have caused the structural abnormality was detected, if 
one or both parents were younger than 16 years, or if one 
or both parents did not or could not provide informed 
consent. All participants gave written informed consent, 
and the study was approved by Research and De-
velopment offices at each participating institution and by 
relevant Research Ethics Committees (including those at 
South Birmingham and Harrow).
Procedures
Parental blood samples were collected for DNA ex traction 
and fetal DNA was obtained from chorionic villi, 
amniotic fluid, or fetal blood that remained after routine 
investigations at the two coordinating centres. This DNA 
was assessed for aneuploidy and CNVs at these centres. 
Parents and fetuses were excluded from subsequent 
analyses if tests revealed aneuploidy or CNVs that 
explained the anomalous structural phenotype of the 
fetus. DNA of parents and fetuses that had not been 
excluded was then shipped to the Wellcome Sanger 
Institute for WES (appendix). Participants were informed 
that the PAGE genetic analyses results would not be 
available during the current pregnancy, and only results 
relevant to the ultrasound scan-detected fetal structural 
anomalies would be reported back to parents. To ensure 
a range of phenotypes, it was agreed before the study that 
the number of fetuses with any specific phenotype would 
be capped at about 20% of the ongoing total.
After WES, we assessed sequence data for candidate 
pathogenic variants from a modified list of genes 
that are likely associated with developmental disorders 
(appendix),16 and we selected rare, protein altering 
variants in which the inheritance pattern of the variant 
matched that of the gene being assessed for clinical 
review (bioinformatic filtering). These variants were 
deemed candidate pathogenic variants and were collated 
for assessment by a clinical review panel (CRP). The 
sequence data that we used to determine likely genes and 
variants associated with developmental disorders are 
available from the European Genome-phenome Archive.
Candidate pathogenic variants were reviewed and clas-
sified by a CRP that comprised at least six partic -
ipants (a clinical geneticist, fetal medicine specialist, 
two clinical scientists, and a bioinformatician) from 
the study team and, usually, clinical geneticist and 
laboratory scientist from the recruitment centre. Initially, 
CRP meetings were face-to-face but, sub sequently, distant 
participants joined by Webex or teleconferencing to review 
anon ymised variant annotation data and clinical find-
ings through the Sapientia version 1.7.5 (Congenica; 
Cambridge, UK) software. The CRP reached a consensus 
decision regarding variant classification (ie, pathogenic, 
likely pathogenic, variant of uncertain significance, likely 
benign, or benign), and to the likelihood that they caused 
the structural abnormality phenotype detected in the 
fetus, based on standard criteria in the UK National 
Health Service laboratories at the time of the relevant CRP 
meeting (these guidelines by the Association of Clinical 
Genetic Science, which are based on American College of 
Medical Genetics and Genomics guidelines, are available 
online). Variants in genes associated with developmental 
disorders that were determined by the CRP to be 
pathogenic or likely pathogenic and causative of the fetal 
phenotype were referred to as diagnostic genetic variants. 
The CRP also agreed on the contribution of a genetic 
variant to fetal structural anomalies (ie, none, uncertain, 
partial, or full) based on the ultrasound findings. In 
accordance with the ethical approval re strictions, patho-
genic or likely pathogenic variants were only reported to 
relevant clinicians to report to the parents if they were 
consid ered causative (partly or fully) of the fetal structural 
anomalies.
During the study, it became apparent that a path ogenic 
RIT1 variant had not been reviewed by the CRP after 
the variant had been removed from the dataset during 
bioinformatic filtering of variants because it had been 
inherited from a parent who was determined to be 
unaffected by developmental disorders. Reanalysis of the 
data for other known pathogenic variants (from the 
ClinVar database of genetic variation and human health) 
in developmental genes then revealed two further similar 
fetuses with an inherited pathogenic variant in PTPN11, 
who had hydrops or large nuchal translucency. Sanger 
sequencing was used to confirm the presence of all 
identified diagnostic genetic variants and research 
reports were issued to the relevant clinician. Benign and 
likely benign variants were not validated or reported, but 
variants of unknown significance (VUS) that the CRP 
considered to have potential clinical usefulness were 
validated. The CRP comprised both core and rotating 
participants, fa cilitating consistency and mitigating 
possible bias in interpretation.
Outcomes
The primary endpoint, which was assessed in all fetuses, 
was the detection of diagnostic genetic variants considered 
to have caused the fetal developmental anomaly. We also 
assessed the prespecified exploratory endpoint of the 
frequency of genetic variants in predefined subgroups of 
fetuses with specific structural anomalies.
Statistical analysis
Variants were annotated with the probability of the 
relevant gene being loss-of-function-intolerant.17 These 
probabilities were compared with the Mann-Whitney 
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U test. The number of diagnostic genetic variants in the 
phenotypic classes were compared with Fisher’s exact 
test, and Bonferroni correction for multiple testing was 
done with the p.adjust R package. All statistical analyses 
were done with R (version 3.1.3).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
The cohort was recruited between Oct 22, 2014, and 
June 29, 2017, and clinical data were collected until 
March 31, 2018. To estimate the number of eligible cases 
that were excluded from WES, a retrospective review 
of 564 eligible fetuses (ie, fetuses with a structural 
abnormality) revealed that 134 (23·8%) samples were 
not sent for WES because of an abnormal quantitative 
fluorescence-PCR analysis (n=97) or chromosomal 
microarray (n=37) finding.
The 610 fetuses (257 female, 353 male) that were eligible 
for WES were categorised into 11 phenotypic classes 
based on the site of the anomalies that were detected by 
ultrasound (appendix). These phenotypic anomaly groups 
ranged from spinal (n=10) to complex or multisystem 
anomalies (ie, in which two or more fetal structural 
anomalies were detected; n=143; appendix). These 
610 fetuses and 1202 matched parental samples (596 fetus-
parental trios, including two sets of twins, and 14 fetus-
parent dyads) were included in the cohort. 321 genetic 
variants (representing 255 potential diagnoses) were 
identified as candidate diagnostic findings from the WES 
data and were reviewed by the CRP (appendix). A mean 
of 0∙42 (SD 0·676) potential diagnoses per fetus was 
reviewed; this value included a mean of 0∙40 (0·636) for 
complete trios (n=596) and 1∙36 (1·393) for dyads (n=14). 
However, phenotypes did not significantly differ between 
trios and dyads.
The CRP assessed variants in 184 different devel-
opmental disorder genes, at a median of one gene in 
each fetus. However, 35 genes were assessed in several 
fetuses (FLNA in five fetuses; HSPG2, RYR1, SYNE1, 
KMT2D, CHD7, and PTPN11 in four fetuses each; 
MECP2, COL1A1, and HUWE1 in three fetuses each; 
and ATP13A2, DNAH5, CDH23, COL18A1, COL11A2, 
LAMA1, MBTPS2, MAMLD1, PKD2, NOTCH1, PROK2, 
FGFR3, BRCA1, CHRNG, COL6A3, ROBO1, TUBB, 
PIEZO1, NRAS, HYDIN, ZC4H2, BCOR, PEX7, EPHB4, 
and RIT1 in two fetuses each; figure 1).
Pregnancy outcomes were available for 474 (78%) of 
610 fetuses. Of these, in 142 (30%) pregnancies, the 
parents opted for termination, 14 (3%) pregnancies ended 
in miscarriage, there were 22 (5%) stillbirths, 14 (3%) neo-
natal deaths, and 282 (59%) were livebirths.
A detailed study of the ethical issues in the PAGE study 
is in progress.18 Possible ethical issues that we noted 
included the identification of potentially pathogenic 
variants that might confer a risk of recurrence of an 
inherited developmental disorder but were unrelated to 
the detected fetal structural anomalies and the iden-
tification of a VUS in a relevant candidate gene; in 
accordance with the ethical approval, these findings were 
not reported to the parents. Postnatally, this issue might be 
handled by more detailed phenotyping or periodic reviews 
but, in the prenatal setting, phenotypic information is 
generally less detailed and delaying a diagnostic decision is 
usually not an option. This decision is particularly difficult 
if the fetal structural anomalies might have a benign 
prognosis, such as talipes equinovarus. Other ethical 
issues regarding not reporting outcomes to parents arose 
with detection of heterozygous pathogenic variants in 
developmental genes associated with autosomal recessive 
disease and detection of pathogenic variants that predict 
late-onset adult disease (eg, increased risk of breast cancer 
in a mother found to be a carrier of a Fanconi anaemia 
gene variant) that was not relevant to the fetal abnormality 
being studied.
The 321 genetic variants (255 potential diagnoses) 
included 301 single nucleotide variants (SNVs) and indels, 
18 CNVs, and two uniparental disomies in 205 (33∙6%) 
of 610 fetuses that underwent WES. 52 (8∙5%, 95% CI 
6∙4–11∙0) fetuses were diagnosed with likely pathogenic 
or pathogenic variants relevant to the phenotypic fetal 
structural anomalies (table 1). 32 (61∙5%) of 52 fetuses 
with a diagnostic genetic finding (ie, a genetic result 
considered to be causative of the structural abnormality 
observed) had a de novo mutation (15 truncating 
mutations, 15 missense mutations, one in-frame 
insertion, and one 41·2 kb de letion), 19 (36∙5%) fetuses 
had inherited the relevant mutations (14 mutations were 
autosomal recessively inherited, and five mutations were 
dominantly inherited disorders), and one (1∙9%) fetus 
had a chro mosome 15 uniparental disomy.
We found that genetic variants were diagnostic (ie the 
variant was considered pathogenic or likely pathogenic 
and causative of the fetal phenotype) in 15 (75∙0%) of 
20 fetuses with de novo protein truncating variants in 
monoallelic genes, 15 (25∙0%) of 60 fetuses with de-novo 
missense variants in monoallelic genes, and 31 (37∙8%) 
of 82 fetuses with de-novo variants in a monoallelic 
disease gene. Genes with diagnostic SNVs and indels 
had a higher median probability of being loss-of-function 
intolerant than non-diagnostic variants (diagnostic 0∙81 
vs non-diagnostic 0∙24; p=0∙0276).
Of the 35 genes with variants reviewed by the CRP in 
more than one fetus, six (17%) genes had variants that 
were diagnostic in more than one fetus (figure 1), and 
diagnostic KMT2D and CHD7 mutations (all de novo 
truncating) were present in fetuses with several phenotypic 
anomalies (KMT2D: one fetus with each of multisystem 
anomalies, cardiac anomalies, and hydrops; CHD7: 
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two fetuses with multisystem anomalies and one fetus 
with cardiac anomalies). PTPN11 variants (all missense, 
one de novo, two inherited) were found in fetuses with 
multisystem anomalies, hydrops, and increased nuchal 
translucency phenotypes. To our knowledge, this PAGE 
cohort includes the first instances of the prenatal 
identification of mutations in several genes (table 2; 
appendix).
The proportion of fetuses with diagnostic genetic 
variants varied between the phenotypic groups (figure 1; 
appendix). The greatest proportion of diagnostic genetic 
variants were found in fetuses with skeletal abnormalities 
(ten [15∙4%] of 65 fetuses with skeletal abnormalities), 
multisystem anomalies (22 [15∙4%] of 143 fetuses with 
multisystem anomalies), and cardiac abnormalities 
(nine [11∙1%] of 81 fetuses with cardiac abnormalities). 
We found diagnostic genetic variants in three (9∙0%) of 
33 fetuses with hydrops and one (10∙0%) of ten fetuses 
with spinal abnormalities. Diagnostic genetic variants 
were found in less than 4% of fetuses in all other groups 
of phenotypic anomalies. After correction for multiple 
testing, the detection of pathogenic or likely pathogenic 
genetic variants in fetuses with multisystem anomalies 
was significantly more frequent than in fetuses with all 
other phenotypes (p=0·01893).
The consequences of a molecular diagnosis might relate 
to both the affected pregnancy and potential future 
pregnancies. None of the diagnostic genetic variants would 
have led to in-utero fetal treatment. However, diagnoses 
during pregnancy could have affected decisions about 
whether to proceed with the pregnancy; for instance, in the 
fetuses with cardiac anomalies, pathogenic or likely 
pathogenic variants were found in genes associated with 
postnatal extracardiac manifestations (such as in KMT2D, 
ANKDR11, SOS1, CCDC103, and CHD7), including 
learning disabilities. Overall 34 (65∙4%) of 52 diagnostic 
genetic variants were associated with learning disabilities 
and, of these, 16 (47·1%) genetic variants were in a fetus 
without brain or multisystem anomalies (table 1). During 
pregnancies, diagnoses might have enabled better post-
natal management (such as monitoring for neonatal 
hypoglycaemia in a fetus with exomphalos and a CDKN1C 
mutation), and it has been suggested that CoQ10 treatment 
might be helpful in COQ9-deficient children.27 Future 
consequences of a positive diagnosis were a low recurrence 
risk in 33 fetuses (5% of all fetuses assessed; 31 fetuses 
with de novo mutations in monoallelic disease genes, 
Figure 1: Features of the potential diagnoses in fetuses with structural 
abnormalities
(A) Number of potential diagnoses per fetus that were reviewed by the clinical 
review panel. (B) Number of potential diagnoses reviewed by the clinical review 
panel by gene, for all genes with a pathogenic or likely pathogenic variant and for 
all genes considered in more than one fetus (regardless of diagnostic status, single 
nucleotide variants and indels only). (C) Proportion of diagnostic genetic variants 
identified in fetuses with each phenotypic abnormality. NT=nuchal translucency.
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one fetus with a de-novo CNV, and one fetus with a uni-
parental disomy) and a high recurrence risk in 19 fetuses 
with inherited variants (3% of all fetuses assessed; 
14 autosomal recessive mutations and five dominant 
disorders).
Of the 52 fetuses with a WES diagnosis of likely path-
ogenic or pathogenic genetic variants, post-mortem or 
postnatal follow up was available in 47 (90·4%) fetuses 
and was consistent with the molecular diagnosis. To our 
knowledge, a postnatal genetic diagnosis has not been 
made in any of the fetuses that were reviewed by the 
CRP and designated as having a variant without clinical 
relevance. Of the 474 fetuses with available pregnancy 
outcome data, pathogenic or likely pathogenic genetic 
variants were detected in 27 (14∙1%) of 192 fetuses that did 
not survive beyond birth, including in two (14%) of 14 mis-
carriages, 20 (14∙1%) of 142 terminations of pregnancy, 
three (13∙6%) of 22 stillbirths, and two (14∙3%) of 
14 neonatal deaths, which was significantly more common 
than in the 20 (7∙1%) of 282 fetuses that were liveborn 
(p=0∙0181; figure 2).
In addition to 52 WES-diagnosed fetuses, a further 
24 fetuses showed genetic variants that were not con-
sidered to be classifiable as diagnostic but merited 
Phenotype Gene Consequence Inheritance Zygosity
PP0087 Skeletal DYNC2H1 Two stop gained mutations Inherited Compound heterozygous
PP0174 Multisystem NRAS Missense variant De novo Heterozygous
PP0184 Cardiac NR2F2 Missense variant De novo Heterozygous
PP0204 Skeletal ZC4H2 Frameshift variant De novo Heterozygous
PP0258 Abdominal MYCN Missense variant Inherited from affected parent Heterozygous
PP0318 Skeletal CHRNG Frameshift variant Inherited Homozygous
PP0333 Cardiac GATA4 Frameshift variant De novo (presumed) Heterozygous
PP0342 Multisystem CHRNG Frameshift variant Inherited Compound heterozygous
PP0384 Brain B3GLCT Splice donor variant Inherited Homozygous
PP0390 Cardiac CCDC103 Missense variant Inherited Homozygous
PP0513 Cardiac DNAH11 Stop gained Inherited Homozygous
PP0555 Multisystem EVC2 Frameshift variant Inherited Homozygous
PP0602 Large NT ≥4·0 NA Uniparental disomy on chromosome 15 Uniparental disomy NA
PP0656 Multisystem PKD1/TSC2 41·2kb deletion De novo (copy number variation) Heterozygous
PP0659 Multisystem RAPSN Splice donor variant Inherited Homozygous
PP0792 Skeletal COL1A1 Missense variant De novo Heterozygous
PP0981 Multisystem GBA Frameshift variant Inherited Homozygous
PP1408 Multisystem SOX9 Missense variant De novo Heterozygous
PP1462 Multisystem BRAF Missense variant De novo Heterozygous
PP1561 Skeletal PIK3CA Missense variant De novo Heterozygous
PP1573 Hydrops KMT2D Frameshift variant De novo Heterozygous
PP1579 Brain TUBB Missense variant De novo Heterozygous
PP1627 Multisystem PIEZO1 Three missense variants Inherited Compound heterozygous
PP1711 Facial or cleft lip and palate SF3B4 Frameshift variant De novo Heterozygous
PP1726 Cardiac TAB2 Frameshift variant De novo Heterozygous
PP1750 Cardiac ANKRD11 Frameshift variant De novo Heterozygous
PP1753 Multisystem CDKN1C Frameshift variant Inherited Heterozygous
PP1780 Multisystem TCTN2 Splice acceptor Inherited Homozygous
PP1795 Multisystem COQ9 Stop gained Inherited Homozygous
PP1807 Large NT ≥4·0 MID1 Stop gained De novo Hemizygous
PP1843 Multisystem KMT2D Stop gained De novo Heterozygous
PP1864 Cardiac KMT2D Splice donor variant De novo Heterozygous
PP1892 Cardiac SOS1 Protein altering variant De novo Heterozygous
PP1934 Skeletal COL1A1 Missense variant De novo Heterozygous
PP1967 Multisystem PTPN11 Missense variant De novo Heterozygous
PP2000 Multisystem RYR1 Stop gained and frameshift variant Inherited Compound heterozygous
PP2009 Skeletal ARCN1 Frameshift variant De novo Heterozygous
PP2015 Multisystem FLNB Missense variant De novo Heterozygous
PP2033 Cardiac CHD7 Frameshift variant De novo Heterozygous
(Table 1 continues on next page)
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further (post-hoc) clinical and molecular investigations 
and these were classified as clinically relevant-VUSs 
(appendix). These findings included a fetus with 
micrognathia, radial aplasia, ulnar and fibular hypoplasia, 
tibial and femoral shortening, and an abnormal lumbar 
spine with com pound heterozygous nonsense 
(2269C→T; Gln757Ter) and missense (1580C→G; 
Thr527Arg) variants in RECQL4. Although the nonsense 
variant was considered pathogenic, the missense sub_
stitution was classified as a VUS. Bi-allelic RECQL4 
Phenotype Gene Consequence Inheritance Zygosity
(Continued from previous page)
PP2039 Hydrops NIPBL Stop gained De novo Heterozygous
PP2141 Skeletal FGFR3 Missense variant De novo Heterozygous
PP2645 Multisystem TFAP2A Missense variant De novo Heterozygous
PP2718 Multisystem CHD7 Stop gained De novo Heterozygous
PP2904 Spinal EPHB4 Frameshift variant De novo Heterozygous
PP2979 Multisystem CHD7 Frameshift variant De novo Heterozygous
PP3168 Multisystem RIT1 Missense variant De novo Heterozygous
PP3246 Skeletal NALCN Missense variant De novo (presumed) Heterozygous
PP3387 Multisystem RAB23 Stop gained Inherited Homozygous
PP3540 Skeletal FGFR3 Missense variant De novo Heterozygous
PP0626 Multisystem RIT1 Missense variant Inherited Heterozygous
PP2567 Hydrops PTPN11 Missense variant Inherited Heterozygous
PP0503 Large NT ≥4·0 PTPN11 Missense variant Inherited Heterozygous
Data are listed by identification numbers given by the clinical review panel. NA=not applicable. NT=nuchal translucency.
Table 1: Diagnostic variants that were identified and classified by the Prenatal Assessment of Genomes and Exomes clinical review panel
Postnatal fetal phenotypes References Number of 
postnatal cases in 
cited references
Prenatal ultrasound scan findings 
(PAGE identifier)
ANKRD11 KBG syndrome, Coffin-Siris-like syndrome, intellectual disability, 
macrodontia, facial dysmorphisms, skeletal anomalies, short 
stature, hearing loss, and recurrent middle palatal abnormalities
19–21 89 Atrioventricular canal defect (PP1750)
ARCN1 Severe micrognathia, microcephaly, short stature with rhizomelic 
shortening, joint laxity, and mild developmental delay and, in 
some cases, cardiac defects, and cleft palate (each in one case)
22 4 Absent or hypoplastic radius, ulnar 
hypoplasia, fibular hypoplasia, and short 
tibia, femur, and humerus (PP2009)
CCDC103 Primary ciliary dyskinesia (including upper and lower airway 
infections, sinusitis, bronchiectasis, dextrocardia or situs inversus, 
atrioventricular septal defects, and immotile sperm)
23–26 14 Complex univentricular heart, double 
outlet right ventricle, transposition great 
arteries, pulmonary stenosis, and likely 
right atrial isomerism (PP0390)
COQ9 Neonatal encephalopathy with lactic acidosis, seizures, global 
developmental delay, hypertrophic cardiomyopathy, and renal 
tubular dysfunction
27,28 2 Dilated loops of bowel, cardiomegaly, 
pericardial effusion, fetal growth 
restriction, anhydramnios (PP1795)
MYCN Feingold syndrome (including oesophogeal and duodenal atresias, 
microcephaly, learning disabilities, and digital anomalies such as 
brachymesophalang or syndactyly), cardiac defects, and renal 
anomalies
29 77 Duodenal atresia (PP0258)
NR2F2 Atrioventricular septal defects, atrial septal defects, hypoplastic 
left heart syndrome, coarctation of the aorta, tetralogy of Fallot, 
and congenital diaphragmatic hernia
30,31 11 Abnormal four-chamber view of the 
heart (PP0184)
TAB2 Frontometaphyseal dysplasia, hypertelorism, wide nasal bridge, 
micrognathia, hearing loss, congenital heart defects (variable), 
scoliosis, and upper limb contractures
32–35 15 Increased nuchal translucency of 
8·0 mm (PP1726)
TUBB Microcephaly, structural brain anomalies (including dysmorphic 
basal ganglia, abnormalities of the corpus callosum, and brainstem 
hypoplasia), learning disability, circumferential skin creases, cleft 
palate, and short stature
36,37 6 Dysgenesis of the corpus
callosum and lissencephaly (PP1579)
ZC4H2 Arthrogryposis multiplex congenita, kyphosis or scoliosis, and 
severe learning disabilities
38 5 Fixed extended knees, rocker bottom feet, 
and a flat forehead (PP204)
PAGE=Prenatal Assessment of Genomes and Exomes.
Table 2: Genes identified by the PAGE clinical review panel that had diagnostic variants without previous prenatal phenotype descriptions
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mutations are associated with radial aplasia and 
hypoplasia syndromes, and we considered further follow 
up to be indicated. In another case (PP0722) a de-novo 
missense KMT2D variant was detected in a fetus with a 
6∙7 mm nuchal translucency during the first trimester. 
In another case (PP1720), an apparently pathogenic de-
novo nonsense variant in CHD7 was detected in a fetus 
with mild lateral ventriculomegaly and no other 
structural brain abnormalities. Although hydrocephalus 
has rarely been reported in conjunction with pathogenic 
CHD7 variants, it was believed that the isolated 
ventriculomegaly could not be unequivocally attributed 
to the CHD7 variant in the absence of any other features 
of CHARGE syndrome. This example illustrates the 
difficulties that can occur in interpreting genotype-
phenotype causality during the prenatal period.With the 
24 cases that showed potentially clinically relevant 
variants in addition to the 52 diagnostic cases, we found 
76 (12·5%, 95% CI 9·9–15·3) of 610 fetuses in which 
WES provided a clinically relevant result.
Discussion
In our large prospective cohort study of 610 fetuses with a 
broad range of fetal structural anomalies that had been 
detected by prenatal ultrasound scan, we identified a 
relevant diagnostic genetic variant in a developmental 
disorder gene in 52 (8∙5%) fetuses. In an additional 
24 (3·9%) fetuses, a variant of potential clinical usefulness 
was identified and reported. Overall, we identified a 
diagnostic or potentially clinically relevant variant in 
76 (12·5%) fetuses. Although some previous studies14 of 
fetal structural anomalies have reported diagnostic genetic 
variants in more than 50% of fetuses with a structural 
abnormality, most previous studies14 comprise small 
numbers of selective cases, and the designation of genetic 
variants as diagnostic was less stringent. The largest 
previous study11 used WES in 84 deceased fetuses and 
found diagnostic genetic variants in 20% of these fetuses. 
Our lower number of fetuses with diagnostic genetic 
variants reflects differences in ascertainment methods: we 
prospectively recruited all suitable cases and undertook 
WES without genetic review (after excluding aneuploidy 
and large CNVs) whereas Yates and colleagues11 studied 
deceased fetuses after termination or spontaneous fetal 
death. Around 60% of our cohort were liveborn (and a 
lower number had diagnostic genetic variants than fetuses 
who did not survive beyond birth), and the number of 
fetuses that did not survive that showed diagnostic genetic 
variants in our study was close to that reported by Yates 
and colleagues.11 The results of genome-wide sequencing 
in unselected idiopathic fetal structural anomalies are 
especially relevant when considering the potential for 
translating WES into clinical practice. We note that, in a 
meeting abstract, Wapner and colleagues39 reported a 
causal pathogenic variant in 7∙5% of sequential cases of 
fetal structural anomalies (and a further 5∙5% had a 
karyotype or chromosomal microarray anomaly).
WES detection of diagnostic genetic variants in fetal 
structural anomalies is significantly less frequent than 
that reported in children with developmental disorders 
(in whom these genetic variants in developmental disorder 
genes have been reported in up to 43% of cohorts) despite 
a similar sequencing and interpretation strategy.16,40 This 
disparity reflects differences in ascer tainment, since the 
previous postnatal cohort16,40 was selected after assessment 
by a clinical geneticist (and therefore enriched for likely 
monogenic disorders), whereas the PAGE cohort includes 
manifestations such as isolated large nuchal translucency, 
isolated talipes, and neural tube defects, all of which have 
a low association with a monogenic basis. Additionally, 
greater imprecision in prenatal versus postnatal pheno-
typing could also contribute (eg, postnatally, expert 
dysmorphology and developmental assessment facilitates 
variant inter pre tation, which increases the frequency at 
which diagnostic genetic variants are detected).
We found diagnostic genetic variants more frequently 
in association with cardiac, complex or multisystem, and 
skeletal anomalies and, to a lesser extent, hydrops fetalis 
and spinal abnormalities; however, diagnostic genetic 
variants were detected in less than 4% of fetuses with other 
types of anomalies. Variants in KMT2D were one of the 
most frequent diagnostic findings, and these variants were 
associated with several phenotypes, including multisystem 
anomalies (PP1843), isolated complex cardiac defects 
(PP1864), and fetal hydrops and cystic hygroma (PP1573). 
KMT2D mutations cause Kabuki syndrome, which is 
characterised postnatally by developmental delay, epilepsy, 
cardiac, genitourinary and musculoskeletal anomalies, 
Figure 2: Pregnancy outcomes associated with different fetal structural anomalies
45 fetuses had abdominal anomalies, 69 fetuses had brain anomalies, 81 fetuses had cardiac anomalies, 23 fetuses 
had thoracic anomalies, 32 fetuses had facial or cleft lip and palate anomalies, 33 fetuses had hydrops, 93 fetuses had 
increased nuchal translucency (more than 4·0 mm), 16 fetuses had renal anomalies, 65 fetuses had skeletal anomalies, 
ten fetuses had spinal anomalies, and 143 fetuses had complex or multisystem anomalies. NT=nuchal translucency.
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and distinctive facial features.41–44 Although the presentation 
of KMT2D mutations with fetal hydrops has been reported 
previously,44,45 the distinctive facial dysmorphology is less 
apparent in infancy than older children, which makes 
diagnosis difficult during the early postnatal period.
To date, prenatal WES studies have implicated many 
developmental genes in fetal structural abnormalities, 
but 19 genes (including KMT2D) have been reported in 
several studies (appendix). To our knowledge, we report 
the first prenatally diagnosed mutations in several genes 
(table 2), including those associated with isolated (NR2F2 
and TAB2) and syndromic congenital heart disease 
(primary ciliary dyskinesia associated with CCDC103 and 
KBG syndrome associated with ANKRD11), which 
indicates that WES can provide important additional 
information on non-cardiac prognosis. WES can also 
provide insight into the risks of recurrence in subsequent 
fetuses to inform future reproductive choices. Although 
19 (36∙5%) of 52 fetuses with diagnostic genetic variants 
in our study were determined to have a high recurrence 
risk, many genetic variants resulted from de-novo 
mutations that were associated with a small increased 
recurrence risk from gonadal mosaicism. In instances of 
genetic variants with a recurrence risk, parents might 
wish to seek preimplantation diagnosis or prenatal 
genetic diagnosis through invasive or non-invasive 
prenatal diagnosis in future pregnancies.46
A limitation of our study was that the protocol does 
not deliver real-time diagnoses during pregnancies. 
However, decisions on variant classification, validation, 
and reporting were based on information that would have 
been available for an ongoing pregnancy and provide 
insights into translating prenatal WES into clinical 
practice. To maximise the informativeness of the WES 
analysis across a range of fetal structural anomalies 
phenotypes, we capped the number of fetuses with 
isolated nuchal translucency that we analysed. At the time 
of the cap, isolated nuchal translucency fetuses accounted 
for 22% of the total cohort. We estimate that, if the cap 
had not been applied, an additional 56 fetuses would 
have been analysed, and we estimate that approximately 
one additional diagnosis would have been made, giving 
an overall estimated proportion of fetuses with diagnostic 
variants of 8%. For rapid and efficient variant 
prioritisation, fetal-parental trio analysis is preferable to 
fetus-only WES because assessment of trios enables 
rapid identification of de-novo variants in monoallelic 
developmental disorder genes and defines whether 
heterozygous pathogenic variants in biallelic genes are 
in cis or in trans. Optimal variant interpretation requires 
a multidisciplinary approach and detailed clinical 
information, including the prenatal ultrasound scan and 
family history, should be available to the CRP; the 
importance of family history was illustrated by the 
familial MYCN variant. After recognising that limited 
clinical information on the parental phenotype (or 
incomplete penetrance, or both) might lead to removal of 
pathogenic inherited developmental disorder gene 
variants from the dataset (as exemplified by Noonan 
syndrome variants in RIT1 and PTPN11), we recommend 
that the bioinformatics pipeline includes strategies to 
address this issue, such as a whitelist of annotated 
pathogenic variants and predicted pathogenic (trun-
cating) variants in developmental disorder genes that are 
not removed from the dataset, even if inherited from an 
apparently unaffected parent. To maximise the number 
of diagnostic variants detected, we analysed variants 
in the 1511 developmental disorder genes included in 
the developmental disorders gene to phenotype panel 
and 117 genes identified to be associated with a pre-
natal presentation from the literature (appendix). This 
approach resulted in about a third of trios having at least 
one potential diagnostic finding. When im plementing 
WES into clinical practice, there is a strong argument for 
curating the developmental disorders gene to phenotype 
list (by the European Bioinformatics Institute) to remove 
genes that are not associated with fetal structural 
anomalies and for using smaller, phenotype-specific 
virtual gene panels, to reduce the number of VUS that are 
irrelevant to the fetal structural anomalies. Careful 
thought is also required to determine which fetal 
structural anomalies cases should be investigated by WES 
or WGS. For non-specific fetal structural anomalies that 
can be associated with a normal or minimal disability 
outcome (such as talipes equinovarous, resolving ven-
triculomegaly, or an isolated small nuchal trans lucency) 
the number of diagnoses by WES can be small, and 
interpreting the clinical significance of a VUS can be 
problematic with a non-specific phenotype.
WES was done at a central sequencing facility that was 
remote from the clinical centres at which the parents 
were recruited but virtual meetings of the CRP enabled 
all relevant, geographically remote specialists (including 
those who would communicate the results to the parents) 
to discuss their findings and reach a consensus. Although 
PAGE results were communicated to women and their 
partners after the pregnancy, our experience highlighted 
some potential ethical issues that are relevant for clinical 
practice. Although many ethical issues (such as incidental 
findings or non-paternity) are not unique to prenatal 
WES or WGS analyses, and can be managed according to 
standard policies, it is essential that parents receive clear 
information regarding which findings will be reported 
(eg, a policy is required that indicates whether pathogenic 
findings in a developmental disorder gene that is not 
known to be associated with the observed phenotype will 
be reported to parents, and such a policy should be 
described when parents give their consent to participate).18 
These practical ethical issues within the PAGE study 
illustrate the value of embedded ethics research, and they 
also highlight the importance of ethics support, training 
for health professionals, and guidelines for clinical 
implementation (as were published in 2018 by the 
International Society of Prenatal Diagnosis).47
For the European Bioinformatics 
Institute gene to phenotype 
panel see www.ebi.ac.uk/
gene2phenotype
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As prenatal WES becomes more widely adopted, it is 
crucial that the clinical and molecular data generated is 
added to a confidential database and is shared widely in an 
anonymous manner (eg, in DECIPHER or ClinVar), to 
improve variant interpretation and recognition of novel 
prenatal genotype-phenotype associations. Such databases 
should be international to facilitate rapid accumulation of 
data. Developments in bioinformatic processing could 
also facilitate better interpretation of variants across dif-
ferent centres.48
In conclusion, we report the largest study to date of WES 
use in a broad range of fetal structural anomalies. Although 
the proportion of fetuses in which we found diagnostic 
genetic variants is lower than that suggested by smaller 
retrospective studies on selected groups, we have found 
that, in subgroups of fetuses with structural anomalies, 
adding WES to chromosomal microarray substantially 
increased the number of fetuses that could be diagnosed 
with genetic variants that are associated with developmental 
disorder genes and improved the prognostic information 
that could be provided for the current and future 
pregnancies (such as recurrence risks). It seems inevitable 
that WES will increasingly be applied for investigating fetal 
structural anomalies, but the PAGE study suggests that 
this method is best performed by targeting those groups in 
which it is most likely to be diagnostic (and avoiding 
situations in which the likely number of diagnoses by this 
method is low and the detection of VUSs would lead to 
uncertainty and dilemmas with regard to clinical man-
agement). Although WGS might be an alternative to 
combined chromosomal microarray and WES analysis 
(and provide added information on non-coding variants) in 
theory, we expect that chromosomal microarray and WES 
will be used until there is clear evidence that WGS is 
superior (for instance, if non-coding variants were to prove 
to be an important cause of fetal structural anomalies). 
Finally, we would emphasise the importance of sharing 
large, carefully curated clinical and genomic datasets to 
address the challenges of incorporating WES and WGS 
into prenatal diagnostics.
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